CL2012002038A1 - Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion. - Google Patents
Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion.Info
- Publication number
- CL2012002038A1 CL2012002038A1 CL2012002038A CL2012002038A CL2012002038A1 CL 2012002038 A1 CL2012002038 A1 CL 2012002038A1 CL 2012002038 A CL2012002038 A CL 2012002038A CL 2012002038 A CL2012002038 A CL 2012002038A CL 2012002038 A1 CL2012002038 A1 CL 2012002038A1
- Authority
- CL
- Chile
- Prior art keywords
- intraocular pressure
- composition
- ylamin
- imidazolin
- elaboration
- Prior art date
Links
- 230000004410 intraocular pressure Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para reducir la presión intraocular que comprende la administración en forma tópica de una composición farmacéutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presión intraocular inferior a la de la línea base; y artículo de elaboración que comprende a dicha composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29691210P | 2010-01-21 | 2010-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002038A1 true CL2012002038A1 (es) | 2012-11-16 |
Family
ID=44169074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002038A CL2012002038A1 (es) | 2010-01-21 | 2012-07-20 | Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9889088B2 (es) |
| EP (1) | EP2525793B1 (es) |
| JP (3) | JP2013518051A (es) |
| KR (1) | KR20120125305A (es) |
| CN (1) | CN102770135A (es) |
| AU (1) | AU2011207301A1 (es) |
| BR (1) | BR112012018154A2 (es) |
| CA (1) | CA2787573A1 (es) |
| CL (1) | CL2012002038A1 (es) |
| CO (1) | CO6592108A2 (es) |
| IL (1) | IL221030A0 (es) |
| MX (1) | MX2012008516A (es) |
| RU (1) | RU2012134065A (es) |
| SG (1) | SG182637A1 (es) |
| TW (1) | TW201141477A (es) |
| WO (1) | WO2011091225A2 (es) |
| ZA (1) | ZA201205470B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| MX2014000871A (es) * | 2011-07-22 | 2014-06-23 | Allergan Inc | Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo. |
| US20140275197A1 (en) * | 2013-03-14 | 2014-09-18 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
| JPWO2019004080A1 (ja) | 2017-06-27 | 2020-04-23 | 国立大学法人 東京大学 | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| EP4736853A2 (en) * | 2020-11-02 | 2026-05-06 | Visus Therapeutics, Inc. | Degradant compound in a medicament |
| EP4429652A4 (en) * | 2021-11-10 | 2025-09-10 | Visus Therapeutics Inc | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) * | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20090182026A1 (en) * | 2005-06-29 | 2009-07-16 | Allergan, Inc. | Alpha 2 adrenergic agonists |
| JP2009525970A (ja) * | 2006-02-06 | 2009-07-16 | ニコックス エス エイ | α２−アドレナリン受容体アゴニストとしてのアプラクロニジンおよびブリモドニジンのニトロオキシ含有誘導体 |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-01-21 CN CN2011800111530A patent/CN102770135A/zh active Pending
- 2011-01-21 KR KR1020127021719A patent/KR20120125305A/ko not_active Withdrawn
- 2011-01-21 AU AU2011207301A patent/AU2011207301A1/en not_active Abandoned
- 2011-01-21 WO PCT/US2011/022001 patent/WO2011091225A2/en not_active Ceased
- 2011-01-21 RU RU2012134065/15A patent/RU2012134065A/ru unknown
- 2011-01-21 TW TW100102411A patent/TW201141477A/zh unknown
- 2011-01-21 SG SG2012053815A patent/SG182637A1/en unknown
- 2011-01-21 JP JP2012550140A patent/JP2013518051A/ja active Pending
- 2011-01-21 EP EP11702342.4A patent/EP2525793B1/en not_active Not-in-force
- 2011-01-21 BR BR112012018154A patent/BR112012018154A2/pt not_active IP Right Cessation
- 2011-01-21 US US13/010,958 patent/US9889088B2/en not_active Expired - Fee Related
- 2011-01-21 CA CA2787573A patent/CA2787573A1/en not_active Abandoned
- 2011-01-21 MX MX2012008516A patent/MX2012008516A/es unknown
-
2012
- 2012-07-19 IL IL221030A patent/IL221030A0/en unknown
- 2012-07-20 ZA ZA2012/05470A patent/ZA201205470B/en unknown
- 2012-07-20 CL CL2012002038A patent/CL2012002038A1/es unknown
- 2012-08-17 CO CO12140238A patent/CO6592108A2/es not_active Application Discontinuation
-
2015
- 2015-10-28 JP JP2015211447A patent/JP2016026206A/ja active Pending
-
2017
- 2017-04-26 JP JP2017086952A patent/JP6466504B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9889088B2 (en) | 2018-02-13 |
| AU2011207301A1 (en) | 2012-08-09 |
| JP2016026206A (ja) | 2016-02-12 |
| MX2012008516A (es) | 2012-10-15 |
| CO6592108A2 (es) | 2013-01-02 |
| WO2011091225A3 (en) | 2012-05-18 |
| JP6466504B2 (ja) | 2019-02-06 |
| JP2017125074A (ja) | 2017-07-20 |
| EP2525793B1 (en) | 2018-09-05 |
| ZA201205470B (en) | 2013-05-29 |
| KR20120125305A (ko) | 2012-11-14 |
| WO2011091225A2 (en) | 2011-07-28 |
| CA2787573A1 (en) | 2011-07-28 |
| BR112012018154A2 (pt) | 2016-04-05 |
| US20110178145A1 (en) | 2011-07-21 |
| CN102770135A (zh) | 2012-11-07 |
| JP2013518051A (ja) | 2013-05-20 |
| IL221030A0 (en) | 2012-09-24 |
| RU2012134065A (ru) | 2014-02-27 |
| SG182637A1 (en) | 2012-08-30 |
| EP2525793A2 (en) | 2012-11-28 |
| TW201141477A (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012393A (es) | Un agente de sostén | |
| AR089339A1 (es) | Articulos para fumar, y otros articulos con emanacion de flujo | |
| FI20116138A7 (fi) | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen | |
| AR112286A2 (es) | Sistema polimérico de lágrimas artificiales | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| DOP2012000245A (es) | Composiciones sólidas | |
| UY34804A (es) | Inhibidores del nampt | |
| MX338015B (es) | Composiciones que comprenden un componente de estabilidad de la vida util. | |
| UA118558C2 (uk) | Пептидна сполука | |
| BR112017023516A2 (pt) | composição de polímero reforçado com fibra, e, artigo. | |
| MX2013000201A (es) | Metodos para suministrar un activo de atencion sanitaria por medio de administrar articulos de cuidado personal que comprenden un filamento. | |
| CL2012002695A1 (es) | Articulo para fumar, que comprende una primera parte que contiene una fuente de material para fumar y una segunda parte que tiene al menos un extremo que esta configurado para desplazarse en relacion con la primera parte, en donde el articulo ademas comprende un agente modificador de humo que se libera en el articulo para fumar; y envase. | |
| CR11369A (es) | Anticuerpo anti-glipican-3 que tiene cineticas mejoradas en el plasma | |
| MX2020003515A (es) | Laminados elasticos con elasticos curvos y metodos para la fabricacion. | |
| MX2015008069A (es) | Conjunto de envasado para dispositivos de administracion de farmacos. | |
| UA110103C2 (uk) | Модифікований туберкульозний антиген | |
| DOP2015000006A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| MX2013012000A (es) | Composicion y metodo para formar una superficie auto-descontaminante. | |
| CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
| CO6900149A2 (es) | Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd) | |
| CR20170314A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| PE20151435A1 (es) | Laquinimod para reducir el dano talamico en la esclerosis multiple | |
| UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. | |
| MX2019005557A (es) | Composicion para el cuidado bucal. | |
| HRP20130082A2 (hr) | Farmaceutski pripravak za produljeno oslobađanje trimetazidina |